Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-316 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-316 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-316 | GENETIC | ALLO-316 is an allogeneic CAR T cell therapy targeting CD70 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Histologically confirmed renal cell carcinoma with a predominant clear cell component. * Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or metastatic setting. * At least one measurable lesion as defined by RECIST version 1.1 * Eastern Cooper...
ALLO-316 is an investigational gene therapy being studied for the treatment of advanced or metastatic clear cell renal cell carcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in a clinical trial to assess its safety and efficacy in this patient population.
ALLO-316 is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALLO. The company is conducting clinical research on this investigational gene therapy for advanced or metastatic clear cell renal cell carcinoma.
ALLO-316 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA. The ongoing Phase 1 trial is active but not recruiting participants, and the drug has received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
ALLO-316 is being studied in a single Phase 1 clinical trial with the identifier NCT04696731. The trial is titled 'Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma' and is being conducted in the United States. The study is active but not recruiting and has a target enrollment of 120 participants.
ALLO-316 is not FDA approved. It is an investigational gene therapy currently in Phase 1 clinical development for advanced or metastatic clear cell renal cell carcinoma. The FDA has granted it Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations, which are intended to expedite development and review of promising therapies.